Immunogenicity of Del19 EGFR mutations in Chinese patients affected by lung adenocarcinoma.

Deng PanDapeng ZhouWeijing CaiWeibo WuWen Ling TanCaicun ZhouYanyan Lou

Published in: BMC immunology (2019)

These findings suggest that Del19 mutations of EGFR, with an estimated frequency of 40% in Chinese lung adenocarcinoma patients, may serve as unique targets for immunotherapy in Chinese lung cancer patients.

Keyphrases

end stage renal disease
small cell lung cancer
ejection fraction
newly diagnosed
prognostic factors
peritoneal dialysis
epidermal growth factor receptor
tyrosine kinase